This is a randomized, double-blind, active-controlled clinical study evaluating the efficacy and safety of Anrikefon (HSK21542) Injection for patient-controlled analgesia (PCA) in patients undergoing thoracoscopic lung surgery. Subjects aged 18-85 years with a postoperative resting NRS score ≥ 4 will be enrolled. Eligible participants will be randomized 1:1 to receive either Anrikefon (HSK21542) or sufentanil via PCA pump for 24 hours post-surgery. The primary endpoint is the 24-hour summed pain intensity difference (SPID₂₄). A total of 88 subjects are planned for enrollment. The study has received ethics committee approval.
Age 18 to 85 years (inclusive), either sex.
Body mass index (BMI) 18.0 to 30.0 kg/m² (inclusive).
American Society of Anesthesiologists (ASA) physical status Class I to III preoperatively.
Undergoing elective thoracoscopic lung surgery under general anesthesia (complete video-assisted thoracoscopic surgery, without conversion to thoracotomy), with successful recovery from anesthesia within 1 hour postoperatively, fully awake, able to accurately complete NRS scoring with an NRS score ≥ 4, and willing to accept the analgesic regimen defined in the study protocol.
Known or suspected allergy or contraindication to any of the study drugs.
History of opioid abuse, drug or alcohol dependence, or current preoperative use of opioids.
Use of analgesic medications (acetaminophen, NSAIDs, opioids, tramadol, etc.) within 24 hours preoperatively.
Uncontrolled severe cardiovascular disease (second-degree or higher atrioventricular block, resting heart rate < 50 bpm, uncontrolled hypertension, myocardial infarction or unstable angina within the past 6 months), hepatic insufficiency (ALT/AST > 2× upper limit of normal), renal insufficiency (eGFR < 30 mL/min/1.73m² or maintenance dialysis), neuropsychiatric dysfunction, or inability to cooperate with pain assessment.
Parallel
Anrikefon Injection
DrugActive ingredient: Anrikefon. Specification: 1 mL: 0.1 mg. Dosage: diluted to working solution of 10 μg/mL in 100 mL; loading dose 1.0 μg/kg; PCA bolus 2 mL per demand; lockout interval 15 min.
Sufentanil Citrate Injection
DrugSpecification: 1 mL: 50 μg. Dosage: 2 μg/kg diluted to 100 mL solution; loading dose 0.1 μg/kg; PCA bolus 2 mL per demand; lockout interval 15 min.
Sum of Pain Intensity Difference over 24 Hours (SPID₂₄)
Number and Dose of Rescue Medication
Incidence of Postoperative Nausea and Vomiting (PONV) at 24 Hours
PCA Pump Demand (Total, Effective, and Delivered Dose)
Time to First Rescue Medication
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
